diabetes management

By Dave Muoio 04:06 pm March 12, 2020
Together in perfect harmony. Dexcom and Welldoc have kicked off a new collaboration that will provide Dexcom G6 continuous glucose monitor users with data-analysis insights from Welldoc's digital diabetes management product, BlueStar. These insights include information on how lifestyle factors such as activity, nutrition, sleep and medication adherence are affecting a user's glucose levels. “Now...
By Dave Muoio 02:26 pm March 3, 2020
It was another strong quarter for the ever-growing Livongo Health, which yesterday reported to investors a 137% rise in year-over-year Q4 revenue from $21.2 million to $50.2 million. Full-year revenues followed a similar path, growing 149% from $68.4 million in 2018 to $169.9 million in 2019. “Livongo finished the year with excellent momentum, exceeding all of our guidance metrics, achieving...
By Dave Muoio 03:22 pm February 26, 2020
Type 2 diabetes patients who received a continuous glucose monitoring (CGM) system as part of a virtual diabetes clinic program improved their HbA1c and near-uniformly said they were comfortable self-inserting a sensor with guidance from a remote coach, according to study data presented by Onduo at an academic conference last weekend. Further, while more than half of the study’s nearly 600...
By Dave Muoio 11:31 am January 16, 2020
Bigfoot Biomedical, a diabetes startup looking to automate insulin delivery via a connected insulin pen, has kicked off its Series C round with an initial tranche of $45 million. The raise is headed once again by Abbott, with prior backers Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management pitching in once again. Alongside the news of its raise, Bigfoot...
By Laura Lovett 02:13 pm January 13, 2020
Dexcom’s G6 Continuous Glucose Monitoring system will soon be integrated with Livongo’s platform, thanks to a new partnership between the two diabetes-focused companies.  G6 users who are also Livongo members will be able to sync their device to the Livongo platform, which will be able to give users insights and health nudges about their behavior based on the CGM reading. The system will also be...
By Dave Muoio 02:13 pm December 16, 2019
The FDA announced Friday a De Novo clearance for an interoperable automated glycemic controller device for use in a hybrid closed-loop diabetes management system. Tandem Diabetes Care’s Control-IQ Technology acts as a new feature for the company’s t:slim X2 insulin pump (which was also cleared by the FDA back in February). The controller algorithm allows the pump and its connected system to...
By Dave Muoio 03:48 pm December 10, 2019
Sanofi announced a major strategy shift today that will end the pharma’s diabetes and cardiovascular R&D efforts in favor of a reinvigorated focus on growing its immunology and vaccine businesses. Among the fallout of this new game plan is Onduo, the pharma’s diabetes management joint venture with Verily that the two companies invested $500 million into back in 2016, according to the company’...
By Dave Muoio 10:52 am December 3, 2019
Dexcom continuous glucose monitor users and their caregivers found themselves in the dark this weekend when a key monitoring feature ceased to function with little to no warning. The feature, called Dexcom Follow, transmits an alert when a CGM user’s blood sugar reaches a dangerous level and is often used by parents monitoring their children’s condition. When unexpected issues brought down the...
By Dave Muoio 11:53 am November 25, 2019
DarioHealth is the latest to bring its mobile-friendly glucose management system to store shelves, with the company announcing today that it will be bringing its so-called “Membership-in-a-Box” to physical retail chains like Best Buy. The offering, already available through Best Buy’s online storefront, consists of the company’s connected blood glucose meter, 25 test strips, 10 lancets, 10 covers...
By Dave Muoio 03:12 pm November 21, 2019
Welldoc is tapping Astellas Pharma to assist Japanese and Asian commercialization efforts for the former’s digital therapeutic for patients with diabetes, the companies announced yesterday. To kick off the deal, Astellas is making an upfront $15 million payment to Welldoc, which will allow the pharma to jointly develop and commercialize the BlueStar product in the region. The two will also be...